Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02818686 · ClinicalTrials.gov registry record · Phase 1
TD-1473 for Active Ulcerative Colitis (UC)
A Phase 1 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02818686 is a Phase 1 study that has completed, run by Theravance Biopharma. The registered enrollment target is 40 participants.
The verdict
NCT02818686, a Phase 1 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TD-1473 in subjects with moderately-to-severely active UC over 28 days. This exploratory study will also serve as a signal seeking endeavor to demonstrate biologic effect associated with TD-1473 through biomarker analysis and clinical, endoscopic, and histologic assessments.
Interventions
- DRUG Placebo
- DRUG TD-1473
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-10-03 |
| Est. Completion | 2018-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02818686
The ClinicalTrials.gov registry entry for NCT02818686 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02818686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02818686 about?
NCT02818686 is a clinical study titled "TD-1473 for Active Ulcerative Colitis (UC)". This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TD-1473 in subjects with moderately-to-severely active UC over 28 days. This exploratory study will also serve as a signal seeking endeavor to demonstrate biologic effect associated with ...
What is the current status of trial NCT02818686?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-10-03. Estimated completion is 2018-03-29.
What interventions are being tested in trial NCT02818686?
The interventions under investigation include: Placebo (DRUG), TD-1473 (DRUG).
Who is sponsoring clinical trial NCT02818686?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.